Endocrinology

Plozasiran, a first-in-class RNA interference therapeutic, reduced triglycerides by 80% and lowered the risk of acute pancreatitis by 83% in patients with familial chylomicronemia syndrome, earning FDA...

Crinecerfont, a first-in-class therapy, improved androgen control and reduced reliance on high-dose glucocorticoids for patients with congenital adrenal hyperplasia.

Individuals with prediabetes who achieve a weight loss of at least 5% experience significant improvements in insulin sensitivity and reductions in visceral fat, suggesting that remission of prediabetes can...

In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing patients with diabetes and the value of utilizing the services of a...

Researchers examined the risk of nephrolithiasis among patients with type 2 diabetes using SGLT2is for treatment.

Researchers sought to determine whether patients with type 2 diabetes and obesity experience continued type 2 diabetes remission.

In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing people with diabetes, the importance of diabetes self-care and...

Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.

Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.

The US Preventive Task Force (USPSTF) released its updated recommendations for screening children and adolescents for lipid disorders.